Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2)

da Silva Zanzarini, Isadora; Henrique Kita, Diogo; Scheiffer, Gustavo; Karoline dos Santos, Kelly; de Paula Dutra, Julia; Augusto Pastore, Matteo; Gomes de Moraes Rego, Fabiane; Picheth, Geraldo; Ambudkar, Suresh V.; Pulvirenti, Luana; Cardullo, Nunzio; Rotuno Moure, Vivian; Muccilli, Vera; Tringali, Corrado; Valdameri, Glaucio

doi:10.1016/j.bioorg.2024.107283

Bioorganic Chemistry

2024

DOI: 10.1016/j.bioorg.2024.107283

|View full text |Cite

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2)

Isadora da Silva Zanzarini,

Diogo Henrique Kita,

Gustavo Scheiffer

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Zheng,

Chang,

Liang

et al. 2024

Cancer Drug Resist

View full text Add to dashboard Cite

Drug resistance is a major challenge in cancer therapy that often leads to treatment failure and disease relapse. Despite advancements in chemotherapeutic agents and targeted therapies, cancers often develop drug resistance, making these treatments ineffective. Extracellular vesicles (EVs) have gained attention for their potential applications in drug delivery because of their natural origin, biocompatibility, and ability to cross biological barriers. Using the unique properties of EVs could enhance drug accumulation at target sites, minimize systemic toxicity, and precisely target specific cells. Here, we discuss the characteristics and functionalization of EVs, the mechanisms of drug resistance, and the applications of engineered EVs to overcome drug resistance. This review provides a comprehensive overview of the advancements in EV-based drug delivery systems and their applications in overcoming cancer drug resistance. We highlight the potential of EV-based drug delivery systems to revolutionize cancer therapy and offer promising strategies for more effective treatment modalities.

show abstract

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Zheng,

Chang,

Liang

et al. 2024

Cancer Drug Resist

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2)

Cited by 1 publication

References 79 publications

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Contact Info

Product

Resources

About